GlassScriptPhysician profile
Naomi Chaney
NPI 1245310127
$3,697.99
in general payments reported to CMS, 2019-2025
29 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $1,016 · 2021: $582 · 2022: $436 · 2023: $263 · 2024: $671 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.11 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,001.40 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $424.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $321.12 | 2019-2025 | Vraylar, Qulipta |
| Amgen INC. | $267.13 | 2019-2025 | Repatha, Otezla, Repatha |
| Teleflex LLC | $179.39 | 2024 | Urolift |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.48 | 2019-2023 | Jardiance |
| Abbott Laboratories | $155.34 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $144.23 | 2020-2024 | |
| Esperion Therapeutics, INC. | $90.96 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $80.88 | 2019-2022 | |
| Exact Sciences Corporation | $80.13 | 2023-2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $77.90 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.38 | 2022-2025 | |
| Boston Scientific Corporation | $75.83 | 2020-2024 | |
| Mannkind Corporation | $74.57 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $65.06 | 2019-2020 | |
| Eisai INC. | $62.32 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $59.45 | 2023-2025 | |
| Lilly USA, LLC | $45.87 | 2020-2022 | |
| Ibsa Pharma INC. | $45.42 | 2020 | |
| Intra-Sana Laboratories | $34.80 | 2021 | |
| Allergan, INC. | $34.18 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.43 | 2021 | |
| Astellas Pharma US INC | $21.42 | 2019 | |
| Dexcom, INC. | $20.88 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $17.97 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $14.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomi Chaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.